Back to results
US 2022/0090082 A1Published application
Gapmer antisense oligonucleotides targeting sars-cov-2 for treating covid 19
AssigneeChildren's National Medical Center
InventorsYi-Wen CHEN, Alexander E. LIU
Life of this patent
Estimating the term…
Abstract
SARS-CoV-2 causes pandemic COVID19. Developing an effective treatment to directly target the virus could significantly impact viral burden in those most vulnerable to the devastating effects of this virus. The invention provides antisense oligonucleotides (AOs) to target the single stranded RNA genome of the SARS-CoV-2 viruses. The administration of AOs can significantly reduce the target viral RNAs.
Claims30
A composition comprising a nucleotide sequence comprising:
- (i) an RNA-binding domain from about 5 to about 30 nucleotides complementary to a region of a SARS-CoV-2 RNA and (ii) at least one locked nucleic acid (LNA) domain comprising from about 1 to about 10 nucleotides;
- at least one 2′-O-methyl (2′-O-Me) domain comprising from about 1 to about 10 nucleotides;
- and/or at least one 2′-O-methoxyethyl (2′-MOE) domain comprising from about 1 to about 10 nucleotides, or a salt thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.